过氧化物酶体增殖物激活受体γ激动剂治疗肺癌的机制及临床证据研究进展  

Research Progress on Mechanism and Clinical Evidence of Peroxisome Proliferator Activated Receptor Gamma Agonist in the Treatment of Lung Cancer

作　　者：魏士雄 WEI Shixiong(Department of Cardiothoracic Surgery,Chinese People's Liberation Army General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院胸心外科,北京市100853

出　　处：《实用心脑肺血管病杂志》2020年第8期136-140,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：肺癌是癌症相关性死亡的主要原因之一,临床上多数肺癌患者确诊时已处于疾病晚期,其5年生存率仅为2%,因此临床亟需探寻肺癌新的预防及治疗方法。近年来逆转细胞形成肿瘤的过程已成为癌症治疗的主要研究方向之一。过氧化物酶体增殖物激活受体(PPARs)是一类由配体激活的核转录因子,属于Ⅱ型核激素受体超家族成员,其中PPAR-γ在脂肪细胞成熟和脂质稳态等过程中具有促分化、抗增殖及促凋亡作用。笔者通过复习国内外相关文献,综述了PPAR-γ激动剂治疗肺癌的机制及临床证据,旨在为PPAR-γ激动剂作为肺癌新的治疗靶点提供一定理论支持。Lung cancer is one of the main causes of cancer-related death.Clinically,most patients are at the advanced stage of disease when they are diagnosed,and their 5-year survival rate is only 2%,so it is urgent to explore new prevention and treatment methods for lung cancer.In recent years,reverse the process of cell formation has become one of the main research directions in cancer treatment.Peroxisoma proliferator activated receptors(PPARs) are a class of nuclear transcription factors activated by ligands,belonging to the type Ⅱ nuclear hormone receptor superfamily.PPAR-γ is known to promote differentiation,antiproliferation and apoptosis in adipocyte maturation and lipid homeostasis.This paper summarizes the mechanism and clinical evidence of PPAR-γ in the treatment of lung cancer by reviewing the related literature at home and abroad,in order to provide some reference for PPAR-γ agonist as a new way to treat lung cancer.

关 键 词：肺癌 过氧化物酶体增殖物激活受体Γ激动剂 治疗靶点 综述 

分 类 号：R734.2[医药卫生—肿瘤]